ADVENT is a medical education program designed to advance our understanding of type 2 inflammation in dermatology, pulmonology, rhinology, and gastroenterology.
ADVENT has been developed in collaboration with over 50 global experts to provide the most up-to-date science on type 2 inflammation, with the objective of advancing clinical management and improving patient care in chronic diseases such as atopic dermatitis, asthma, COPD, CRSwNP, eosinophilic esophagitis, or prurigo nodularis. This educational platform is intended for healthcare professionals only.
Type 2 asthma is a common phenotype of asthma, characterized by key cytokines IL-4, IL-13, and IL-5, as well as elevated type 2 inflammatory biomarkers as FeNO, and eosinophils, or the need for maintenance OCS. Type 2 inflammation is evident in up to 88% of patients with severe asthma, representing a substantial portion of the disease burden associated with asthma. Explore the resources on the ADVENT Asthma Learning Hub to better understand the role of type 2 inflammation in asthma.
COPD, a progressive respiratory condition, is defined by persistent airflow limitation and a spectrum of clinical presentations. There are multifaceted factors that contribute to its development and progression including complex inflammatory processes that drive the disease’s pathogenesis. A profound understanding of COPD’s inherent heterogeneity recognizing that it is not a singular disease, but rather a collection of phenotypes with varying underlying mechanisms and responses to treatment is crucial for advancing personalized patient care. Visit the COPD learning hub focused on key scientific education on chronic obstructive pulmonary disease, featuring ADVENT resources.